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Abstract: Circadian clock gene PER3 and its length polymorphism may have a role in oncogenesis as clock genes act as 
key regulators of cell cycle and DNA repair pathways. The polymorphism may affect the condition of patients who 
show disrupted circadian rhythm due to tumor development. The aim was to assess the association between PER3 poly- 
morphism and onco-hematological diseases, and analyze whether this variant has an impact on patient’s functionality. 
We conducted a case-control study on 125 patients with onco-hematological diseases and 310 control patients. PER3 
allelic variants were detected by using polymerase chain reaction. Sociodemographic data and information on patient’s 
habits and functionality were obtained through questionnaire. Genotypes 4/5 + 5/5 showed an odd ratio (OR) = 1.39, 
with no statistical significance. However, those genotypes were associated with a two-fold increase in the risk of 
acute/chronic lymphoblastic/myeloblastic leukemia, taken all together. The occurrence of “changes in humor during last 
two months” was significantly associated with onco-hematological diseases. “Fatigue on awakening” and “self-reported 
snore” were associated with cases carrying the 4/5 or 5/5 genotypes. The results suggested that PER3 polymorphism 
may have a role in the risk of leukemia, and might be a possible marker for individual differences in susceptibility to 
sleep disruption. This work provides insights for the identification of individuals at high risk of cancer, and those who 
are more susceptible to circadian disruption, which may decrease the physiological defenses against the tumor. 
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he circadian system regulates metabolism and  
energy homeostasis on a daily basis in order to 
maintain vital processes and prepare the organism 
to respond to predictable/daily environmental condi-
tions[1]. Accordingly, most of the mammalian physiology 
is regulated at some points by the main circadian clock 
which is located at the hypothalamic suprachiasmatic  
nuclei (SCN). Circadian coordination is known to be 
T 
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extremely important for healthy physical and mental 
function, as many diseases display disruption of cir-
cadian rhythms[2,3]. Several studies have reported cir-
cadian alterations in cancer patients and tumor-bearing 
animals[4,5]. Moreover, current data have suggested that 
this disruption could be more than a consequence of 
cancer development and it may act as a risk factor[6,7]. In 
2007, the International Agency for Research on Cancer 
(IARC, World Health Organization) concluded that 
shiftwork that involves circadian disruption is probably 
carcinogenic to humans (Group 2A)[8]. Besides the core 
clock at the SCN, peri- pheral tissues also have circadian 
clocks which show internal desynchronization under 
pathological conditions[9]. 
At molecular level, the circadian clock involves tran-
scriptional-translational negative feedback loops, rhyth-
mic production and degradation of protein complexes 
that turn off their own production[10,11]. Some circadian 
genes involved in the loop also control the transcription 
of other genes, such as clock-controlled genes (CCG), 
which  represent 2%–10% of the mammalian ge-
nome[12]. Although the majority of the CCG show tis-
sue-specific expression patterns, a few sets of them are 
expressed in multiple organs and encode key regulators 
of the cell cycle, deoxyribonucleic acid (DNA) dam-
age/repair pathways, and cell death[6,13]. 
Period (PER) genes are part of the core of the mecha-
nism involved in the circadian clocks. Period circadian 
clock 3 (PER3) is a member of the PER family, and in 
humans it contains a variable number tandem repeat 
(VNTR) polymorphism, consisting of a 54-bp coding 
region repeated 4 or 5 times[14]. These repeats are of in-
terest because it included numerous potential phos- 
phorylation sites. Thus, they could affect post-transla-
tional modification and stability of the protein. Several 
studies hypothesized that PER3 VNTR polymorphism 
may alter the susceptibility to cancer[15]. Moreover, vari-
ants in the circadian genes (CRY2, PER1, NPAS2 and 
CSNK1E) have been associated with different types of 
cancer, including non-Hodgkin lymphoma, prostate 
and breast cancer[16-20]. Studies on the expression patterns 
of circadian genes (PER3 and CCG) show that there are 
significant differences between tumor tissue and the 
normal one adjacent to the tumor[21-22]. All these data 
show a possible role of PER3 and its allelic variants in 
oncogenesis, and its potential use as a susceptibi-
lity biomarker. 
As mentioned above, many physiological processes 
are affected by the tumor development, resulting in dis-
rupted circadian rhythms in cancer patients. On the other 
hand, the central clock regulates sleep, mood, food intake 
and attention[23]. The connection between cancer, clock 
and behavior is quite relevant, given that living with 
cancer is emotionally exhausting. In fact, cancer patients 
undergo sickness behavior, a cluster of symptoms that 
include lethargy, depression, fever, hyperalgesia and de-
creased social interaction, which might be the result 
of both the disease and the treatment[24]. PER3 has been 
reported to play a role in modulating sleep homeostasis 
in humans[25]. Thus, the VNTR polymorphism may have 
an impact on the patient’s performance while facing 
changes in the circadian rhythm.  
According to the Atlas of Cancer Mortality pub-
lished by the Ministry of Health[26], the onco-hematolo-
gic diseases (leukemia, lymphomas and multiple myelo-
ma) were the cause of over 18,500 deaths in Argentina 
from 2007–2011. These disorders exhibit an incidence of 
almost 850,000 cases/year worldwide, as reported by the 
IARC in its previous GLOBOCAN 2012 report[27]. In 
recent years, only a few studies addressed the connec-
tion between blood cancer and circadian rhythm, since 
most of the work on the topic focused on breast, prostate 
and colon cancers. 
The aim of this work is to study the association be-
tween the VNTR of PER3 and onco-hematological di- 
seases, and analyze whether this variant has an impact on 
the patient’s functionality in terms of fatigue, sleep and 
humor, among other variables.  
Materials and methods 
A case-control study consisting of 125 patients with 
onco-hematological diseases and 310 control patients 
was conducted. All the participants were recruited be-
tween June 2013 and March 2015 at the Unit of Diagno-
sis, Treatment and Support for Hematological Diseases 
of Hospital Prof. Dr. Rodolfo Rossi (La Plata, Buenos 
Aires, Argentina). 
The cases included patients diagnosed with acute 
lymphoblastic leukemia (ALL, N = 10), acute myeloblas-
tic leukemia (AML, N = 18), chronic lymphoblastic leu-
kemia (CLL, N = 10), chronic myeloblastic leukemia 
(CML, N = 20), multiple myeloma (MM, N = 29), Hodg-
kin lymphoma (HL, N = 18) and non-Hodgkin lymphoma 
(NHL, N = 20). The controls were patients frequently 
visiting the unit for routine checks of disorders unrelated 
to cancer, or preoperative blood analyses. All the partici-
pants resided in Argentina. Cases and controls with pre-
vious history of cancer or pathologies which are closely 
related to onco-hematological diseases were excluded 
from the study.  
Patients participated in this study upon signing an in-
formed consent. A questionnaire was used to obtain    
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sociodemographic data and information about habits and 
functionality of patients (previous 2 months), such as 
changes in weight (± 5 kg), changes in appetite (either 
increase or decrease), changes in humor (worse or better), 
presence of physical/mental fatigue, difficulty in sleeping 
(especially when trying to fall asleep), fatigue on awak-
ening, waking up several times at night, early morning 
awakening and difficulty to fall asleep again, snoring, 
and good sleep quality. All the surveys were con-
ducted by the same person. Blood samples were col-
lected and kept in tubes with ethylenediaminetetraacetic 
acid (EDTA). Then, the DNA was extracted from 
whole blood using salting out methods.  
The detection of PER3 allelic variants was per-
formed by PCR, using the primers 5ʹ-TGGTCCCAG-
CAGTGAGAGT-3ʹ forward and 5ʹ-CCAGATGCTGCT-
CTACCTGAACC-3ʹ reverse. Reaction conditions were 
as follows, in a final volume of 15 μL: 1× buffer, 50 ng 
DNA, 0.25 mmol/L each primer, 200 μmol/L dNTPs, 
1.5 mmol/L MgCl2, 0.45 U Taq Platinum Polymerase 
(Life Technologies) and H2O up to 15 μL. The PCR  
cycling consisted of an initial denaturation at 95°C for 5 
min, followed by 30 cycles at 95°C for 1 min, fol-
lowed by annealing at 57°C for 1 min and elongation 
at 72°C for 1 min, with a final extension at 72°C for 5 min. 
The products (261 bp and 315 bp) were visualized in 2% 
(w/v) agarose gels, stained with GelRed (Biotium Inc.). 
Odds ratio (OR) and confidence interval at 95% 
(CI95%) were calculated to assess the association be-
tween each variable studied and hematological disease. 
Chi-square (Chi2) test was applied to obtain the statistical 
significance of the association. Analyses were performed 
with STATA 11.1[28] and Epidat 4.0[29]. Allele and geno-
type frequencies were calculated and tested for Hardy- 
Weinberg equilibrium using GenAlEx 6.5[30,31]. P-values 
≤0.05 were considered statistically significant. The sam-
ple size of this study achieved 80% power to detect an 
OR = 2.00. 
Ethics statement 
All the procedures performed in studies involving human 
participants were in accordance with the ethical stan-
dards of the institutional and/or national research com-
mittee and together with the 1964 Helsinki declaration 
and its later amendments or comparable ethical standards. 
The informed consent was obtained from all participants 
in this study and this study was approved by the ethics 
committee of the hospital. 
Results 
Study population 
In this association study, a total of 125 cases were com-
pared to 310 controls, and they were all patients from the 
Hospital Prof. Dr. Rodolfo Rossi. Demographic charac-
teristics are listed in Table 1. The missing data for each 
variable were not included in the analysis or detailed in 
the tables. The maximum number of missing data in a 
variable was 18, representing 4.14% of the samples. The 
height and weight data were excluded due to >10% 
missing data. There was no significant difference in the 
mean age of cases and controls. Women showed lower 
risk of the disease compared to men (OR = 0.52, CI95% 
0.34–0.82, p = 0.003). Higher levels of education (>12 
years) were significantly related with an increased risk, 
compared to those who completed primary school or less 
(OR = 3.68, CI95% 1.82–7.40, p < 0.001 adjusted for 
age and sex). Marital status did not show relation with 
the disease.  
PER3 polymorphism 
Genotype and allele frequencies for the VNTR of PER3 
were in accordance with Hardy-Weinberg equilibrium 
(Table 2). Considering the 4/4 genotype as reference,  
genotype 4/5 and the homozygous 5/5 did not show as-
sociation with hematological cancer (OR = 1.50, CI95% 
0.95–2.35 and OR = 1.80, CI95% 0.84–3.95, respec-
tively). The trending p-value was 0.039. 
Genotypes 4/5 and 5/5 analyzed together showed an 
OR = 1.39, with no statistical significance (p = 0.175 
adjusted for age, sex, educational level and city of resi-
dence). However, those genotypes were associated with a 
two-fold increase in the risk of ALL, CLL, AML and 
CML, taken all together (OR = 1.99, CI95% 1.06–3.74, p 
= 0.032 adjusted for age, sex, educational level, and city 
of residence). There was no significant association be-
tween the polymorphism and the other diseases (MM, 
HL and NHL data are not shown).  
Functionality  
With respect to functionality variables evaluated in the 
questionnaire, only “changes in humor” showed signifi-
cant associations with the onco-hematological diseases 
under study (Table 3, OR and p values adjusted for age, 
sex, educational level and city of residence). Variables 
“better mood during the last two months” (OR = 4.28, 
CI95% 2.00–9.12, p < 0.001) and “worse mood” (OR = 
2.00, CI95% 1.17–3.42, p < 0.001) were significantly 
associated with the disease. 
Impact of PER3 polymorphism on  
patient’s behavior  
Table 4 shows the distribution of PER3 genotypes in  
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Table 1 Demographic characteristics of the population under study 
 
Cases N = 125 Controls N = 310 
OR (CI95%) p 
Mean (SD) Mean (SD) 
Age (years) 48.5 (16.6) 51 (18.5) – 0.507 
 N (%) N (%)   
Sex     
Male 74 (59.2) 134 (43.2) Ref. 
0.003 
Female 51 (40.8) 176 (56.8) 0.52 (0.34–0.82) 
Education     
≤7 years (completed primary school or less) 55 (44.0) 174 (56.3) Ref. 
<0.001a 12 years (completed secondary school) 48 (38.4) 115 (37.2) 1.2 (0.73-1.95) 
>12 years (completed college)  22 (17.6) 20 (6.5) 3.68 (1.82–7.40) 
Marital status     
Single 27 (21.6) 79 (25.5) Ref.  
Partner/Married 86 (68.8) 162 (52.3) 1.7 (0.99–2.95) 0.055a 
Divorced/Separated 5 (4.0) 27 (8.7) 0.64 (0.21–1.90) 0.420a 
Widowed 7 (5.6) 42 (13.5) 0.75 (0.27–2.13) 0.595a 
   a: Adjusted for age and sex. OR (CI95%): odds ratio and confidence interval 95%. Ref: reference category. SD: standard deviation. p < 0.05       
considered statistically significant.    
 
Table 2 Association between PER3 polymorphism and onco-hematological diseases. Genotype and allele frequencies for the VNTR 
are also shown 
PER3 polymorphism 
Cases N = 120 N (%) Controls N = 297 N (%) 
OR (CI95%) p Chi2 & p trend 
N (%) N (%) 
Allele frequencies      
4-rep 0.69 0.76 − − − 
5-rep 0.31 0.24    
Genotype frequencies      
4/4 58 (48.3) 176 (59.3) Ref.  
4.26 
p trend = 0.039 4/5 50 (41.7) 101 (34.0) 1.50 (0.95–2.35) 0.077 
5/5 12 (10.0) 20 (6.7) 1.82 (0.84–3.95) 0.130 
4/4 58 (48.3) 176 (59.3) Ref. 
0.175a − 
4/5 + 5/5 62 (51.7) 121 (40.7) 1.39 (0.86–2.25) 
LMC/LLC/LMA/LLA (N = 58)      
4/4 23 (39.7) 176 (59.3) Ref. 
0.032a − 
4/5 + 5/5 35 (60.3) 121 (40.7) 1.99 (1.06–3.74) 
a: Adjusted for age, sex, educational level and city of residence. OR (CI95%): odds ratio and confidence interval 95%. Ref.: reference category.             
p < 0.05 considered statistically significant. 
 
controls and cases for each behavior variables analyzed. 
Variables “fatigue on awakening” and “self-reported snore” 
were associated with cases carrying the 4/5 or 5/5 geno-
type (p = 0.003 and p = 0.036 respectively, adjusted for 
age and sex). The rest of the variables included in the 
questionnaire did not show statistically significant     
associations. 
Discussion 
Patients who go through an oncologic disease may un-
dergo circadian disruption as a reaction of physiology to 
tumor presence or as the result of endocrine response to 
physical/emotional demands of the illness. Cancer pa-
tients take longer time to fall asleep, wake up more often, 
spend more time in bed and nap more frequently than 
healthy individuals[32,33]. On the other hand, genetic, en-
vironmental or behavioral factors may favor circadian 
disruption, predisposing patients to tumor develop-
ment[34]. Several studies have demonstrated that 
long-term night shiftwork is a prognostic value for breast 
cancer[35,36]. 
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Table 3 Association between functionality variables and onco-hematological diseases 
 
Cases N = 125 Controls N = 310 
OR (CI95%) p 
  N (%) N (%) 
Weight 
 
 
  
No changes 50 (42.0) 140 (47.0) Ref. 
 
Increase/decrease <5 kg 31 (26.0) 84 (28.2) 1.03 (0.61–1.74) 0.902 
Increase/decrease ≥5 kg 38 (32.0) 74 (24.8) 1.43 (0.86–2.38) 0.161 
Appetite 
 
 
  
No changes 72 (60.0) 188 (62.1) Ref. 
 
Increase 20 (16.7) 58 (19.1) 0.9 (0.50–1.60) 0.721 
Decrease 28 (23.3) 57 (18.8) 1.28 (0.75–2.17) 0.355 
Humor 
 
 
  
No changes 50 (41.0) 163 (53.8) Ref. 
 
Better mood 22 (18.0) 24 (7.9) 4.28 (2.00–9.12) <0.001a 
Worse mood 50 (41.0) 116 (38.3) 2.00 (1.17–3.42) 0.001a 
Physical/mental fatigue 
 
 
  
No 60 (48.0) 128 (41.4) Ref. 
0.211 
Yes 65 (52.0) 181 (58.6) 0.77 (0.49–1.19) 
Fatigue on awakening 
 
 
  
No 77 (62.1) 199 (64.6) Ref. 
0.623 
Yes 47 (37.9) 109 (35.4) 1.11 (0.71–1.75) 
Difficulty sleeping 
 
 
  
No 67 (53.6) 175 (56.8) Ref. 
0.541 
Yes 58 (46.4) 133 (43.2) 1.14 (0.73–1.77) 
Waking up several times at night 
 
 
  
No 44 (35.2) 122 (39.3) Ref. 
0.420 
Yes 81 (64.8) 188 (60.7) 1.19 (0.76–1.89) 
Early morning awakening 
 
 
  
No 95 (99.0) 207 (96.7) Ref. 
0.252 
Yes 1 (1.0) 7 (3.3) 0.31 (0.01–2.49) 
Snore 
 
 
  
No 44 (36.4) 100 (34.8) Ref. 
0.769 
Yes 77 (63.6) 187 (65.2) 0.94 (0.59–1.50) 
Good sleep quality 
 
 
  
Yes 66 (54.1) 159 (51.3) Ref. 
0.599 
No 56 (45.9) 151 (48.7) 0.89 (0.57–1.39) 
a: Adjusted for age, sex, educational level and city of residence. OR (CI95%): odds ratio and confidence interval 95%. Ref: reference category. p < 0.05 
considered statistically significant.
In our study, behavior variables such as fatigue,    
difficulty in sleeping, waking up several times at night 
or changes in appetite or weight did not associate with 
hematological cancer. This is probably because the 
study was hospital-based and more than 75% of the 
control patients were taking medication at the time of 
the inter- view, e.g., for different cardiologic or gastric 
disorders (data not shown). Moreover, a survey includ-
ing >1,700 individuals from Buenos Aires (Argentina), 
Sao Pablo (Brazil), and Mexico DF (Mexico) showed 
that 2/3 of interviewed people experienced some type 
of sleeping difficulty during the previous year, and 
more than 25% individuals were moderately/severely 
affected[37]. Among them, the most common sleep dis-
turbances reported within the last 12 months were: 
waking in the middle of the night (65%), waking up 
tired (55%), difficulty in sleeping and restarting it after 
an interruption (50%), or waking up too early (35%)[37]. 
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Table 4 Distribution of PER3 genotypes among cases and controls, and its association with functionality variables 
  Cases Controls 
pa,b 
  4/4 4/5 + 5/5 4/4 4/5 + 5/5 
Weight      
No changes 22 (40.7) 27 (45.0) 69 (40.8) 62 (53.5) 
0.318 Increase/decrease <5 kg 12 (22.2) 18 (30.0) 53 (31.4) 28 (24.1) 
Increase/decrease ≥5 kg 20 (37.1) 15 (25.0) 47 (27.8) 26 (22.4) 
Appetite      
No changes 32 (57.2) 35 (59.3) 101 (58.7) 80 (67.8) 
0.180 Increase 12 (21.4) 8 (13.6) 36 (20.9) 19 (16.1) 
Decrease 12 (21.4) 16 (27.1) 35 (20.4) 19 (16.1) 
Humor      
No changes 21 (37.5) 26 (42.6) 87 (50.9) 69 (58.0) 
0.561 Better mood 12 (21.4) 10 (16.4) 16 (9.4) 8 (6.7) 
Worse mood 23 (41.1) 25 (41.0) 68 (39.7) 42 (35.3) 
Physical/mental fatigue      
No 29 (50.0) 27 (43.6) 69 (39.4) 54 (44.6) 
0.159 
Yes 29 (50.0) 35 (56.4) 106 (60.6) 67 (55.4) 
Fatigue on awakening      
No 42 (72.4) 31 (50.8) 108 (61.7) 83 (69.2) 
0.003 
Yes 16 (27.6) 30 (49.2) 67 (38.3) 37 (30.8) 
Difficulty sleeping      
No 31 (53.4) 31 (50.0) 94 (53.7) 75 (62.5) 
0.168 
Yes 27 (46.6) 31 (50.0) 81 (46.3) 45 (37.5) 
Waking up several times at night      
No 21 (36.2) 21 (33.9) 66 (37.5) 53 (43.8) 
0.335 
Yes 37 (63.8) 41 (66.1) 110 (62.5) 68 (56.2) 
Early morning awakening      
No 42 (100.0) 48 (98.0) 118 (97.5) 82 (95.4) 
0.990 
Yes 0 1 (2.0) 3 (2.5) 4 (4.60) 
Snore      
No 25 (44.6) 19 (31.2) 47 (29.2) 43 (38.0) 
0.036 
Yes 31 (55.4) 42 (68.8) 114 (70.8) 70 (62.0) 
Good sleep quality      
Yes 32 (55.2) 31 (52.5) 87 (49.4) 67 (55.4) 
0.320 
No 26 (44.8) 28 (47.5) 89 (50.6) 54 (44.6) 
a: p-values for interaction between functionality variables and PER3 genotype were estimated using a logistic regression model extended to include 
the interaction term. b: Adjusted for age and sex. p < 0.05 considered statistically significant. 
 
 
In fact, sleeping difficulties affect a significant pro-
portion of people living in urban areas who are experienc-
ing social jet-lag and night light pollution[38,39]. Since 
these disturbances are even worse for chronic diseases, 
we did not observe significant differences between cases 
and controls in our study. However, “feeling positive or 
negative changes in humor” was significantly associated 
with onco-hematological diseases (p < 0.001 adjusted for 
age, sex, educational level and city of residence). Several 
factors in a cancer patient should be noted, such as his-
tory and family background, physical and psychological 
impact of the illness, psychic resources and medical care. 
Cancer patients often suffer from adjustment disorders 
and anxiety generated by the diagnosis, prognosis, the 
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wait for results, family conflicts, fear of recurrence and 
death, abnormal metabolic states and drugs, such as cor-
ticosteroids[40]. Therefore, patient’s mood will depend on 
the interaction between all these factors in a more com-
plex scenario than any other chronic diseases. In fact, the 
depression in cancer patients is twice as likely compared 
to the patients hospitalized due to other medical prob-
lems[40]. 
In the present study, the VNTR polymorphism of 
PER3 increased the risk of onco-hematological dis-
eases by 39%. During the analysis of leukemia separately 
from the rest of the conditions, the genotypes 4/5 and 5/5 
were observed to be associated with a statistically sig-
nificant increased risk (OR = 1.99, CI95% 1.06–3.74, p = 
0.030 adjusted for age, sex, educational level and city of 
residence). Individual studies showed no conclusive re-
sults for the above-mentioned polymorphism[19,20,41]. A 
meta-analysis carried out by Geng and colleagues[15] 
combining three retrospective studies (2,492 cancer pa-
tients and 2,749 controls) reported that individuals with 5 
repetition alleles had 17% increased risk of cancer com-
pared to individuals with the 4 repetition alleles. How-
ever, this association was not statistically significant. A 
study on an American population reported a significantly 
higher risk of breast cancer among premenopausal 
women with the 5 repetition    alleles[16], but a larger 
replication with Chinese samples did not show signifi-
cant association results[20]. So far, there are no studies 
which evaluate the possible association between the 
VNTR with any of the blood cancers. 
When we analyzed the distribution of PER3 geno-
types among controls and cases, we found that cancer 
patients with the 4/5 or 5/5 genotypes had greater fatigue 
on awakening. Voinescu et al.[42] focused on PER3 geno-
types and applied a battery of questionnaires to a popula-
tion with self-reported sleep problems, finding that 
homozygotes for the 5 alleles showed difficulties in get-
ting up more frequently than those with the 4 alleles or 
heterozygotes. In another study, a group of 24 healthy 
volunteers were subjected to sleep deprivation. It was 
observed that during the morning hours of the second 
day of sleep deprivation which was approximately 2–6 h 
after the melatonin peak, the performance (working 
memory, attention and psychomotor performance) dete-
riorated significantly in 5/5 individuals, whereas the de-
cline was lower in 4/4 ones[25,43]. Based on the available 
data described above, our results suggest that cancer pa-
tients with 4/5 or 5/5 genotype may suffer fatigue more 
intensely, since they combine circadian disruption from 
the pathology itself with an increased susceptibility to 
sleep deprivation due to PER3 genotype. It is important 
to take into account that our results were obtained with a 
non-validated questionnaire and more accurate appro-
aches could be achieved using validated tools. 
Case-control studies, as other population analyses, 
should also consider the ethnic composition of the group 
under study as allele frequencies vary among different 
populations. For the same reason, caution should be ex-
ercised when extrapolating results from one population 
to another.  
Conclusion 
All these data show that the VNTR of PER3 may have a 
role in the risk of leukemia, and it may be a significant 
marker for individual differences in sleep, vulnerability 
to sleep disruption and circadian phase misalignment. 
The investigations aimed at elucidating the molecular 
connection between circadian genes and carcinogenesis 
will be helpful in identifying individuals at a higher risk 
or more susceptible to circadian disruption. It is worth to 
note that circadian disruption may decrease the physio-
logical defenses against the tumor. 
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